Advertisement

Reactions Weekly

, Volume 1738, Issue 1, pp 39–39 | Cite as

Antineoplastics/clarithromycin

Tumour lysis syndrome: case report
Case report
  • 54 Downloads

Reference

  1. Mikala G, et al. Minimal residual disease negativity after molecularly targeted venetoclax therapy of secondary plasma cell leukemia with translocation T(11;14). HemaSphere 2 (Suppl. 1): 994 abstr. PB2233, 14 Jun 2018. Available from: URL: http://doi.org/10.1097/HS9.0000000000000060 [abstract] - Hungary

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations